Panel orders audit of stem cell program
By San Francisco Chronicle,
San Francisco Chronicle
| 03. 09. 2006
State lawmakers on Wednesday ordered an audit of the institute and committee created to spend $7 billion of voter-approved bonds aimed at funding stem cell research.
The Legislature's Joint Legislative Audit Committee voted unanimously to require the state auditor to review both the California Institute for Regenerative Medicine and the Independent Citizen's Oversight Committee. The stem cell program, approved by voters in November 2004, has come under fire for spending money on such things as public relations and lobbying and because many of the members of the oversight committee represent groups that may be awarded grants.
"I believe the audit will help ensure that the program is on sound footing as it moves into its grant-making phase next year,'' said state Sen. Deborah Ortiz, D-Sacramento, who called for the audit.
State Auditor Elaine Howle said the audit would evaluate the program's strategic plans and whether the two bodies are properly identifying and avoiding conflicts of interest. She also will look at whether the programs have the right controls in place to ensure they comply with state laws.
The audit will...
Related Articles
By Editors, Nature | 08.18.2026
Shinya Yamanaka doesn’t see himself as a celebrity. But people do recognize the stem-cell researcher when he’s out for a run, often while training for a marathon, on the streets of Kyoto, Japan.
Many of them call out words of...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...
By Carl Zimmer and Marco Hernandez , The New York Times | 07.01.2026
Scientists have long dreamed of discovering the alchemy by which chemicals can be turned into life. On Wednesday, a team at the University of Minnesota announced that it had taken a major step toward that vision.
Blending together dozens of...
By Marisa Flook , BioNews | 06.29.2026
An anti-ageing gene therapy not approved by the US Food and Drug Administration (FDA) is set to be offered by an American company at overseas clinics outside of US jurisdiction.
The treatment, developed by Minicircle from Austin, Texas, uses a...